Reading view
Do Phone-Use Agents Respect Your Privacy?
A Semi-amortized Lifted Learning-to-Optimize Masked (SALLO-M) Transformer Model for Scalable and Generalizable Beamforming
General scales unlock AI evaluation with explanatory and predictive power
Nature, Published online: 01 April 2026; doi:10.1038/s41586-026-10303-2
A fully automated methodology based on rubrics capturing a broad range of cognitive and intellectual demands is illustrated using LLMs and tasks, demonstrating a new way to evaluate the capabilities of AI systems and anticipate their performance.Author Correction: Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes
Nature, Published online: 31 March 2026; doi:10.1038/s41586-026-10389-8
Author Correction: Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomesBeyond Preset Identities: How Agents Form Stances and Boundaries in Generative Societies
SynLeaF: A Dual-Stage Multimodal Fusion Framework for Synthetic Lethality Prediction Across Pan- and Single-Cancer Contexts
UAV-DETR: DETR for Anti-Drone Target Detection
Edge Radar Material Classification Under Geometry Shifts
Dominant clones leverage developmental epigenomic states to drive ependymoma
Nature, Published online: 25 March 2026; doi:10.1038/s41586-026-10270-8
Single-nucleus chromatin and RNA sequencing identifies epigenetic chromatin domains that confer vulnerability to paediatric brain tumours such as ependymomas, providing insight into the development of such tumours despite ‘quiet’ genomes.ESM1 drives cancer angiogenesis and bevacizumab resistance via trioleate synthesis
Neoplasia. 2026 May;75:101298. doi: 10.1016/j.neo.2026.101298. Epub 2026 Mar 20.
ABSTRACT
BACKGROUND: Hepatocellular carcinoma (HCC) exhibits high recurrence rates and limited therapeutic options. Endothelial cell-specific molecule 1 (ESM1) and angiopoietin-like 4 (ANGPTL4) are implicated in tumor progression, yet their synergistic role in HCC lipid metabolism and angiogenesis remains unexplored.
METHODS: We integrated multi-omics approaches, including RNA sequencing, metabolomics, and immunoprecipitation-mass spectrometry, in HCC cell lines and patient-derived xenograft models. Key experiments involved Co-IP, Western blotting, tube formation assays, and clinical tissue microarray analysis to validate the ESM1-ANGPTL4-FASN-trioleate axis.
RESULTS: ESM1 and ANGPTL4 formed a positive feedback loop, stabilizing fatty acid synthase (FASN) to promote trioleate synthesis. Trioleate activated the NF-κB/IL-17 pathway in HCC cells and upregulated CD99 in endothelial cells, driving angiogenesis. In vivo, ESM1/ANGPTL4 knockdown suppressed tumor growth, which was rescued by trioleate supplementation. Clinical data revealed elevated ESM1/ANGPTL4 expression in bevacizumab-resistant HCC, correlating with poor prognosis.
CONCLUSIONS: The ESM1-ANGPTL4-FASN-trioleate axis orchestrates metabolic reprogramming and endothelial activation, representing a promising therapeutic target. Future studies should explore combination therapies targeting this axis and overcoming bevacizumab resistance in HCC.
PMID:41864037 | PMC:PMC13019581 | DOI:10.1016/j.neo.2026.101298